Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer

Table 1 Patients characteristics. Data shown are number (%) or median (range)

Characteristic	CRR	RO	P
n	22	25	NS
Age	65 (49-83)	63 (43-76)	NS
Sex (male)	13 (59%)	12 (48%)	NS
Tumor site			NS
Head	20 (91%)	20 (80%)
Body		3 (12%)
Tail
Diffuse	2 (9%)	2 (8%)
Tumor size (mm)	24 (10-41)	29 (10-150)	NS
Tumor type			NS
Ampullary cancer	4 (18%)	4 (16%)
Ductal adenocarcinoma	15 (68%)	14 (56%)
Cystadenocarcinoma	2 (9%)	4 (16%)
Invasive IPMT	1 (5%)	3 (12%)
Tumor stage			NS
IA	4 (18%)	0
IB	4 (18%)	5 (20%)
IIA	7 (32%)	9 (36%)
IIB	7 (32%)	11 (44%)
Lymph node positive	7 (32%)	11 (44%)	NS

CRR: chemoradiation and resection; RO: resection only.

Table 2 Complications

	CRR	RO
Infection
Wound infection/prolonged antibiotic therapy	1,25	13
Pneumonia	1	1
Ileus/delayed gastric emptying	2	0
Postoperative bleeding and reoperation	21	2
Postoperative intestinal haemorraghia: no reoperation	1	1
Central venous catheter in pleural place	1	0
Stroke during the postoperative time	0	11
Vascular injury: occlusion of hepatic artery: immediate reconstruction	0	1
Reoperation: broken drain	11	0
Leakage of gastroenteral anastomosis	21	0
Death	21	0
Complicated patients rate	10/22	8/25

1 or 2 same patient; CRR = chemoradiation and resection; RO = resection only.

Table 3 Median survival time in different cancers

	CRR median months(95% CI)	RO median months(95% CI)
All cancers	30.2 (25.5, 34.9)	35.9 (10.5, 61.3)
LNN negative	30.2 (17.9, 42.4)	37.4 (7.8, 6.7)
LNN positive	27.0 (0, 55.2)	20.7 (16.7, 34.6)
Ductal adenocancers	27.0 (5.5, 48.4)	20.2 (0, 52.0)
LNN negative	30.0 (9.9, 50.5)	20.2 (19.6, 20.3)
LNN positive	27.0 (0, 55.2)	39.0 (0, 110.5)
Ampullar cancers	39.4 (5.9, 72.8)
Cystadenocancers	20.7 (00, 48.2)

CRR: chemoradiation and resection, RO: resection only; LN: lymph node.